Researchers Examine Combination Chemotherapy in Patients With Advanced Prostate Cancer

Researchers Examine Combination Chemotherapy in Patients With Advanced Prostate Cancer
Currently, patients with metastatic castration-resistant prostate cancer (mCRPC) have been treated with cytotoxic chemotherapy with the sequential use of single agent taxanes such as docetaxel and cabazitaxel, used as a “first-line” and “second-line” treatments, respectively. During the American Society of Clinical Oncology meeting a team of researchers at The University of Texas MD Anderson Cancer Center presented the results of a clinical trial whre they examined the use of combination therapy with two or more chemotherapy agents in advanced disease. The efficacy of using only cabazitaxel versus cabazitaxel in combination with carboplatin was compared in patients with mCRPC. For this study a total of 160 men were randomized to receive treatment with either the single or dual chemotherapy drug regimen for up to 10 chemotherapy cycles. The researchers tracked changes in blood levels of prostate-specific antigen (PSA), Progression Free Survival an
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *